TY - JOUR
T1 - Mortality from cancer among US hemodialysis patients, 1995-2005
AU - Foley, Robert N.
AU - Roberts, Tricia L.
AU - Liu, Jiannong
AU - Gilbertson, David T.
AU - Arneson, Thomas J.
AU - Dunning, Stephan
AU - Collins, Allan J.
PY - 2010/6
Y1 - 2010/6
N2 - Background/Aims: Concern has emerged that erythropoiesis-stimulating agents (ESAs) may decrease survival for cancer patients; many patients beginning dialysis have previous cancer diagnoses. As ESA doses have more than tripled in the USA since ESAs were introduced, we aimed to compare annual trends in cancer-specific mortality rates among incident maintenance hemodialysis patients. Methods: This national, retrospective, incident cohort study included 873,493 patients aged ≥20 years who initiated hemodialysis between 1995 and 2005. Cancer-specific mortality rates were adjusted for baseline characteristics, determined from the Centers for Medicare & Medicaid Services (CMS) Medical Evidence Report (form CMS-2728). Follow-up extended to December 31, 2006. Cause of death was ascertained from the Death Notification (form CMS-2746). Results: Crude first-year cancer-specific mortality rates, per 1,000 patient-years, 1995-2005, were as follows: 13.8, 13.7, 14.2, 14.9, 13.8, 15.4, 15.4, 16.5, 16.4, 15.8, 15.2. Mortality rates remained stable year to year within subsequent follow-up intervals; for the first and last annual cohorts, mortality rates by follow-up interval were: year 2, 9.1 and 8.7; year 3, 8.6 and 8.3; years 4-5, 7.9 and 6.8. Annual comparisons were similar after adjustment for patient characteristics at dialysis initiation. Conclusion: Cancer-specific mortality rates remained stable among US hemodialysis patients between 1995 and 2005.
AB - Background/Aims: Concern has emerged that erythropoiesis-stimulating agents (ESAs) may decrease survival for cancer patients; many patients beginning dialysis have previous cancer diagnoses. As ESA doses have more than tripled in the USA since ESAs were introduced, we aimed to compare annual trends in cancer-specific mortality rates among incident maintenance hemodialysis patients. Methods: This national, retrospective, incident cohort study included 873,493 patients aged ≥20 years who initiated hemodialysis between 1995 and 2005. Cancer-specific mortality rates were adjusted for baseline characteristics, determined from the Centers for Medicare & Medicaid Services (CMS) Medical Evidence Report (form CMS-2728). Follow-up extended to December 31, 2006. Cause of death was ascertained from the Death Notification (form CMS-2746). Results: Crude first-year cancer-specific mortality rates, per 1,000 patient-years, 1995-2005, were as follows: 13.8, 13.7, 14.2, 14.9, 13.8, 15.4, 15.4, 16.5, 16.4, 15.8, 15.2. Mortality rates remained stable year to year within subsequent follow-up intervals; for the first and last annual cohorts, mortality rates by follow-up interval were: year 2, 9.1 and 8.7; year 3, 8.6 and 8.3; years 4-5, 7.9 and 6.8. Annual comparisons were similar after adjustment for patient characteristics at dialysis initiation. Conclusion: Cancer-specific mortality rates remained stable among US hemodialysis patients between 1995 and 2005.
KW - Cancer
KW - Erythropoiesis-stimulating agent
KW - Hemodialysis
KW - Mortality
UR - http://www.scopus.com/inward/record.url?scp=77951957990&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951957990&partnerID=8YFLogxK
U2 - 10.1159/000303754
DO - 10.1159/000303754
M3 - Review article
C2 - 20453497
AN - SCOPUS:77951957990
SN - 0250-8095
VL - 31
SP - 518
EP - 526
JO - American Journal of Nephrology
JF - American Journal of Nephrology
IS - 6
ER -